Pharmaceutical name Novo Nordisk A/S (NYSE:NVO), the maker of weight-loss drugs Wegovy and Ozempic, is in the spotlight today after announcing roughly 9,000 job cuts and slashing its full-year guidance. The company, which is seeing increased competition, is hoping to save $1.3 billion annually through its major restructuring plan. BMO Securities reiterated its "market perform" rating after news. This comes just one day after Bernstein Securities upgraded the stock to "outperform" from "market perform," citi ...